Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALEC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Latozinemab | Neurodegenerative Diseases | Phase 3 · NCT06111014 | Terminated |
| Part 1 Blinded - AL001 | Frontotemporal Dementia | Phase 3 · NCT04374136 | Terminated |
| Part 2 (OLE Treatment) - AL001 | Frontotemporal Dementia | Phase 3 · NCT04374136 | Terminated |
| AL001 | Frontotemporal Dementia | Phase 2 · NCT03987295 | Completed |
| AL002 | Alzheimer's Disease | Phase 2 · NCT05744401 | Terminated |
| GSK4527226 | Alzheimer's Disease | Phase 2 · NCT07105709 | Recruiting |
| AL003 | Healthy | Phase 1 · NCT03822208 | Completed |
| Osugacestat (AL101) | Healthy | Phase 1 · NCT04111666 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALEC holds $138.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.2M/quarter from operations, an estimated runway of 14.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 42 · Elevated
Together with the $100.0 million upfront payment we received subsequent to September 30, 2026, under the Genentech License Agreement, net of the $15.0 million payment made to Spur under the Spur Agreement on November 2, 2026, and the net proceeds from the October 2026 underwritten offering, we anticipate that our…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALEC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | Institution (13G, 5%+) | 12,772,152 | 8.58% | 2026-10-16 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 9,374,267 | 6.30% | 2026-09-11 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 7,500,000 | 5.04% | 2026-10-19 |
| BlackRock, Inc. | Institution (13G, 5%+) | 5,784,214 | 3.89% | 2026-03-31 |
| Arnon Rosenthal Chief Executive Officer, Director · +3.92M options |
Insider | 3,514,600 | 2.36% | 2026-10-13 |
| Sara Kenkare-Mitra President and Head of R&D · +18,250 options |
Insider | 501,652 | 0.34% | 2025-12-03 |
| Neil Lindsay Berkley CFO & Chief Business Officer · +403,000 options |
Insider | 395,216 | 0.27% | 2026-10-14 |
| Grace Wong-Sarad Principal Accounting Officer · +219,355 options |
Insider | 161,570 | 0.11% | 2026-10-13 |
| Louis J Jr Lavigne Director · +9,450 options |
Insider | 138,661 | 0.09% | 2026-06-17 |
| Richard H Scheller Director · +9,450 options |
Insider | 134,899 | 0.09% | 2026-06-17 |
| Kristine Yaffe Director · +9,450 options |
Insider | 124,109 | 0.08% | 2026-06-17 |
| Elizabeth A. Garofalo Director · +9,450 options |
Insider | 118,650 | 0.08% | 2026-06-17 |
Share count 148,877,074 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALEC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →